News and Trends 2 May 2016
Galapagos and AbbVie expand their Cystic Fibrosis collaboration
Galapagos and AbbVie expand their ongoing collaboration in Cystic Fibrosis. With a growth in the portfolio, Galapagos' milestones increase from…
AbbVie
- Latest Posts
News and Trends 9 Mar 2016
Boehringer Ingelheim Gets €540M upfront for the next Potential Antibody Blockbuster
Boehringer Ingelheim (Germany) has entered a new collaboration with AbbVie (US) to develop two new candidates for immune diseases, including…
News and Trends 4 Mar 2016
The Best Selling Biologic of All Time now chased by New Phase III Biosimilar
Merck (Germany) has initiated a phase III trial for a biosimilar of AbbVie's Humira, to treat Chronic plaque psoriasis. This is…
News and Trends 3 Mar 2016
Why is J&J getting rid of Galapagos’ shares, when Everyone else is Buying?
J&J has sold over 2 million of Galapagos' shares, which had been inherited from previous acquisitions, reducing its equity in…
ADVERTISEMENT
News and Trends 17 Feb 2016
After a Deal with Gilead, Galapagos is Still Doing Phase II Trials with AbbVie
Galapagos (Belgium) is moving forward with their cystic fibrosis drug candidate after promising Phase I results - and still in collaboration with…
News and Trends 13 Jan 2016
UK Biotech starts 2016 by signing a (Massive?) Immuno-Oncology Deal with AbbVie
This year has started with a rush of deals for many Biotechs. F-Star another such company, now signing up for…
News and Trends 22 Dec 2015
Dutch Organ-on-Chip Biotech Hauls in €1.5M Funding from Pharma Syndicate in Project Against Animal Testing
Mimetas from Leiden (NL) has now been financed to develop an Organ-on-Chip (tissue model) to specifically test Neurotoxicity, as a…
News and Trends 18 Dec 2015
Finally! Galapagos New Mystery Partner to Replace AbbVie Revealed in €2Bn Deal
At last! We now know the fate of Galapagos Phase III Rheumatoid Arthritis drug after AbbVie's shocking abandonment. The Mystery…
News and Trends 4 Nov 2015
Last exclusive interview from #BIO-Europe 2015: Andre Hoekema, SVP Corporate Development of Galapagos
And here is the fourth interview I did at BIO-Europe 2015. This time, I am with Andre Hoekema, top-executive from…
News and Trends 15 Oct 2015
Ablynx richly rewarded for MSD’s Nanobody Proof in Immuno-Oncology
Ablynx - the Belgian nanobody biotech (which uses monoclonal antibodies of Alpacas), has now achieved it's first pre-clinical milestone in…
ADVERTISEMENT
News and Trends 12 Oct 2015
Roche dishes out €509M for a Humanized antibody against Rheumatoid Arthritis
Adheron Therapeutics is a small California (US) biotech which has developed a phase I monoclonal antibody (mAb) therapy for inflammatory…
News and Trends 9 Oct 2015
Fixing the ‘Galapagos-AbbVie Disaster’ through a Cystic Fibrosis Therapy
As we reported last Monday, the AbbVie-Galapagos relationship has proven to be rather rocky as of late, with dramatic action…
News and Trends 3 Oct 2015
What Happened this Week? Abbvie abandons Galapagos, CRISPR Patent war to end and AI to exploit UK’s 100k genomes
Monday: AbbVie abandons Galapagos phase III and stock plummets 39% (and still dropping) Tuesday: Will Roche lose it’s Worldwide Leading position in…
News and Trends 29 Sep 2015
Could an Alpaca’s monoclonal antibodies be used to treat an ultra-rare blood disease?
Ablynx's Nanobody platform has used the smaller than human monoclonal antibodies from an alpaca to develop the phase III Orphan…
News and Trends 28 Sep 2015
AbbVie abandons Galapagos phase III and stock plummets 39% (and still dropping)
What was AbbVie thinking? Backing out of a $1.4Bn deal to support Belgian biotech Galapagos' rheumatoid arthritis candidate through its…
News and Trends 25 Sep 2015
Roche’s patent halts an Amgen biosimilar debut
Amgen has had great success with its Avastin biosimilar, used as an inhibitor of angiogenesis in tumor growth. However, despite…
ADVERTISEMENT
News and Trends 6 Aug 2015
Now it’s Clear, AbbVie Has to Buy Galapagos’ Drug
Galapagos just disclosed new good results of its Phase 2B study in rheumatoid arthritis. The drug could be a lifesaver for…
News and Trends 27 Jul 2015
Ablynx and MSD upgrade their €1.7Bn deal to gigantic €5.7Bn
Using camel antibodies as drugs, sounds crazy? Belgian Ablynx is exactly doing that and has been very successful so far. It's…
News and Trends 11 May 2015
Are AbbVie and J&J already fighting to acquire Galapagos’ pipeline?
Ten years ago, Galapagos completed its initial public offering with a dual listing in Amsterdam and Brussels. Since then, Galapagos…
News and Trends 4 Sep 2014
Art Levinson says goodbye to Roche and will focus on Calico’s development
Roche announced today that Arthur D. Levinson has resigned from the Board of Directors, effective immediately. Arthur D. Levinson made…